Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bayer

Showing results (541-550 of 555) with videos related to

Pageof 56
Sort By:
International Journal of Cancer|July 11, 2025
Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trialMilena Beierlein, Lothar Häberle, Naiba Nabieva, et al.
International Journal of Cancer|March 23, 2019
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patientsNaiba Nabieva, Lothar Häberle, Sara Y Brucker, et al.
Geburtshilfe Und Frauenheilkunde|May 1, 2024
Correction: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace StudyCarolin C Hack, Nicolai Maass, Bahriye Aktas, et al.
Breast (Edinburgh, Scotland)|January 21, 2020
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patientsC C Hack, L Häberle, S Y Brucker, et al.
Breast Care (Basel, Switzerland)|December 7, 2016
Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM StudyPaul Gaß, Peter A Fasching, Tanja Fehm, et al.
Geburtshilfe Und Frauenheilkunde|January 9, 2015
Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM StudyP A Fasching, T Fehm, S Kellner, et al.
Integrative Cancer Therapies|September 16, 2016
Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM StudyCarolin C Hack, Peter A Fasching, Tanja Fehm, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patientsN Nabieva, S Kellner, T Fehm, et al.
Breast Cancer Research and Treatment|January 4, 2019
Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancerMarius Wunderle, Jutta Pretscher, Sara Y Brucker, et al.
BMC Cancer|June 23, 2019
Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM studyMarkus Wallwiener, Naiba Nabieva, Manuel Feisst, et al.
Pageof 56

Showing results (541-550 of 555) with videos related to

Sort By:
Pageof 56
International Journal of Cancer|July 11, 2025
Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trialMilena Beierlein, Lothar Häberle, Naiba Nabieva, et al.
International Journal of Cancer|March 23, 2019
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patientsNaiba Nabieva, Lothar Häberle, Sara Y Brucker, et al.
Geburtshilfe Und Frauenheilkunde|May 1, 2024
Correction: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace StudyCarolin C Hack, Nicolai Maass, Bahriye Aktas, et al.
Breast (Edinburgh, Scotland)|January 21, 2020
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patientsC C Hack, L Häberle, S Y Brucker, et al.
Breast Care (Basel, Switzerland)|December 7, 2016
Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM StudyPaul Gaß, Peter A Fasching, Tanja Fehm, et al.
Geburtshilfe Und Frauenheilkunde|January 9, 2015
Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM StudyP A Fasching, T Fehm, S Kellner, et al.
Integrative Cancer Therapies|September 16, 2016
Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM StudyCarolin C Hack, Peter A Fasching, Tanja Fehm, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patientsN Nabieva, S Kellner, T Fehm, et al.
Breast Cancer Research and Treatment|January 4, 2019
Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancerMarius Wunderle, Jutta Pretscher, Sara Y Brucker, et al.
BMC Cancer|June 23, 2019
Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM studyMarkus Wallwiener, Naiba Nabieva, Manuel Feisst, et al.
Pageof 56